Coronary Artery DiseaseNCT07180368
Assessment and Management of Multiple Drug Use in Elderly Chronic Disease Patients
An observational study of Coronary Artery Disease and Diabete Mellitus, run by Xijing Hospital at 1 site in China.
Trial summary
The purpose of this observational study is to understand the impact of polypharmacy on the prognosis of elderly patients with chronic diseases. The main research question it aims to address is: Does polypharmacy affect the prognosis of elderly patients with chronic diseases? Elderly patients with chronic diseases will… Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Coronary Artery Disease, Diabete Mellitus, Chronic Kidney Disease
- How many people
- 2,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Oct 2024to 30 Sep 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Elderly patients with chronic diseases and multiple comorbidities
Who may be able to join
- Patients aged 65 years or older with at least one chronic disease
Who cannot join
- Patients without chronic diseases
- Patients refused to participate in the study
- Patients with unstable vital signs
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
The purpose of this observational study is to understand the impact of polypharmacy on the prognosis of elderly patients with chronic diseases. The main research question it aims to address is:
Does polypharmacy affect the prognosis of elderly patients with chronic diseases? Elderly patients with chronic diseases will be asked to complete online survey questions regarding their disease prognosis over a 2-year period.
- Conditions
- Coronary Artery Disease, Diabete Mellitus, Chronic Kidney Disease, Hypertension, Heart Failure, Hyperlipidemia
- Medical subject headings
- Coronary Artery Disease, Diabetes Mellitus, Renal Insufficiency, Chronic, Hypertension, Heart Failure, Hyperlipidemias, Obesity, Overweight
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessing the current status of polypharmacy in elderly patients with chronic diseases in Shaanxi Province via cluster sampling questionnaire survey
A cluster sampling method was used to conduct a survey on elderly patients with chronic diseases in Shaanxi Province. A questionnaire survey was conducted in different regional locations to collect detailed medication information from patients, such as the number of chronic diseases (types), the types of medications used (types), specific drug names, medication costs (yuan), and duration of medication use (months). Medication habits, such as whether the medication is prescribed by a hospital, purchased from a pharmacy, recommended by friends, or promoted through advertisements, etc. Specific items include concerns about drugs and current physical discomforts. A 5-point Likert scale was adopted, where 1 point indicates "strongly disagree" and 5 points indicate "strongly agree". After questionnaire collection, combined with Beers, STOPP/START, and Chinese elderly PIM criteria, a polypharmacy evaluation and management strategy for these patients was developed.
Measured: Start from enrollment to the end of the study at 2 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2025
- Study start1 Oct 2024
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Xijing Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07180368
- Sponsor's protocol ID
- ky20252065-F-1
- Status last verified
- Jun 2025
- First submitted
- 29 Jun 2025
- Last updated
- 18 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment and Management of Multiple Drug Use in Elderly Chronic Disease Patients
- ClinicalTrials.gov ID
- NCT07180368
- Acronym / sponsor ID
- ky20252065-F-1
- Conditions
- Coronary Artery Disease, Diabete Mellitus, Chronic Kidney Disease, Hypertension, Heart Failure, Hyperlipidemia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Xijing HospitalUniversity, hospital or other
- Study start
- 1 Oct 2024 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 18 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this observational study is to understand the impact of polypharmacy on the prognosis of elderly patients with chronic diseases. The main research question it aims to address is:
Does polypharmacy affect the prognosis of elderly patients with chronic diseases? Elderly patients with chronic diseases will be asked to complete online survey questions regarding their disease prognosis over a 2-year period.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Elderly patients with chronic diseases and multiple comorbidities
Key inclusion criteria (1 listed)
- Patients aged 65 years or older with at least one chronic disease
Key exclusion criteria (3 listed)
- Patients without chronic diseases
- Patients refused to participate in the study
- Patients with unstable vital signs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Assessing the current status of polypharmacy in elderly patients with chronic diseases in Shaanxi Province via cluster sampling questionnaire survey
Time frame: Start from enrollment to the end of the study at 2 years.
A cluster sampling method was used to conduct a survey on elderly patients with chronic diseases in Shaanxi Province. A questionnaire survey was conducted in different regional locations to collect detailed medication information from patients, such as the number of chronic diseases (types), the types of medications used (types), specific drug names, medication costs (yuan), and duration of medication use (months). Medication habits, such as whether the medication is prescribed by a hospital, purchased from a pharmacy, recommended by friends, or promoted through advertisements, etc. Specific items include concerns about drugs and current physical discomforts. A 5-point Likert scale was adopted, where 1 point indicates "strongly disagree" and 5 points indicate "strongly agree". After questionnaire collection, combined with Beers, STOPP/START, and Chinese elderly PIM criteria, a polypharmacy evaluation and management strategy for these patients was developed.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2025.
Related trials for Coronary Artery Disease
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
Active, not recruitingPhase 3
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Coronary Artery Disease
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
Active, not recruiting
Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography
Coronary Artery Disease
Recruiting
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
Cardiovascular Diseases, Myocardial Ischemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease and Diabete Mellitus, run by Xijing Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ming Yuan, MD, PhD (029-84775188, 1446534236@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessing the current status of polypharmacy in elderly patients with chronic diseases in Shaanxi Province via cluster sampling questionnaire survey (time frame: Start from enrollment to the end of the study at 2 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2025.